Treatment News

Moleculin Announces New Data Discovery Confirming Significant Increase in Potential to Starve Cancerous Tumors

3.4 from 9 votes
Wednesday, October 10, 2018

HOUSTON - Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company focused on the development of oncology drug candidates, all of which are based on license agreements with The University of Texas System on behalf of the M.D. Anderson Cancer Center,  announced that new data relating to its molecule WP1122 will be presented at the upcoming Society for Neuro-Oncology Annual Scientific Meeting.

“We continue to make progress in the development of our inhibitor of glycolysis, WP1122,” commented Dr. Donald Picker, Moleculin’s Chief Science Officer.  “We believe that we have discovered new data during our IND-enabling research with animals that confirms a highly beneficial metabolism of WP1122 and  significant organ accumulation of the inhibitor of glycolysis in the brain and also in the pancreas.  This is especially significant because both brain and pancreatic tumors are highly dependent upon glucose for survival and WP1122 appears to have the ability to inhibit glycolysis, the process by which these tumors convert glucose into energy.”

Walter Klemp, Moleculin’s Chairman and CEO added, “Metabolic inhibition of tumors is conceptually a very important approach, and we believe we have a clear translational focus. We have been pushing hard to prepare WP1122 for Investigational New Drug (IND) status.  It is encouraging to have discoveries during this process that appear to confirm the initial premise and give us more hope that WP1122 could become an important new way to deal with difficult cancers like glioblastoma and pancreatic cancer.”

The Society for Neuro-Oncology is a multidisciplinary organization dedicated to promoting advances in neuro-oncology through research and education.  Now in its twenty fourth year, the Society continues to grow and mature as the premier North American organization for clinicians, basic scientists, nurses and other health care professionals whose focus is central nervous system tumors in children and adults.  This year’s Annual Scientific Meeting will be held November 15 – 18, 2018 at the Marriott Hotel in New Orleans, Louisiana.

About Moleculin Biotech, Inc.
Moleculin Biotech, Inc. is a clinical stage pharmaceutical company focused on the development f oncology drug candidates, all of which are based on discoveries made at M.D. Anderson Cancer Center. Our clinical stage drugs are Annamycin, an anthracycline designed to avoid multidrug resistance mechanisms with little to no cardiotoxicity being studied for the treatment of relapsed or refractory acute myeloid leukemia, more commonly referred to as AML, and WP1066, an immuno-stimulating STAT3 inhibitor targeting brain tumors, pancreatic cancer and AML. We are also engaged in preclinical development of additional drug candidates, including additional STAT3 inhibitors and compounds targeting the metabolism of tumors.

For more information about the Company, please visit

Joe Dorame, Robert Blum or Joe Diaz
Lytham Partners, LLC

Source: Moleculin
3.4 from 9 votes
Free Newsletter
Trending News
by Abidemi Uruejoma
by Abidemi Uruejoma
by Abidemi Uruejoma